Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs?
Bazelier, Marloes T., Gallagher, Arlene M., van Staa, Tjeerd-Pieter, Cooper, Cyrus, Leufkens, Hubert G. M., Vestergaard, Peter and de Vries, Frank (2012) Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs? Pharmacoepidemiology & Drug Safety, 21, (5), 507-514. (doi:10.1002/pds.3234). (PMID:22392882).
Download
Full text not available from this repository.
Description/Abstract
PURPOSE:
Clinical and observational studies suggest that use of thiazolidinediones (TZDs) is associated with an increased fracture risk. In addition, type 2 diabetes mellitus (T2DM) is a risk factor for osteoporotic fracture. Our aim was to estimate fracture risks in TZD users and users of other antidiabetic drugs, classified according to proxies of disease severity.
METHODS:
We conducted a population-based cohort study utilizing the Dutch PHARMO database (1998-2008). PHARMO links pharmacy-dispensing data to the National Hospital Registry. Oral antidiabetic users (n = 123,452) were matched 1:4 by year of birth and sex to non-users. Cox proportional hazards models were used to estimate hazard ratios (HRs) of fracture in TZD users. We created a proxy indicator for disease severity. The first stage was defined as current use of either a biguanide or a sulfonylureum, the second stage as current use of a biguanide and a sulfonylureum at the same time, the third stage was assigned to patients using TZDs and the fourth stage to patients using insulin.
RESULTS:
The risk of osteoporotic fracture was increased 1.5-fold (HR 1.49, 95%CI 1.28-1.73) in patients who currently used TZDs (stage 3), and for patients using insulin (stage 4), the risk was increased 1.2-fold (HR 1.24, 1.14-1.36), as compared with controls. In the first and second stages, risks were lower: HR 1.11 (1.06-1.17) for stage 1 and HR 1.03 (0.96-1.11) for stage 2.
CONCLUSIONS:
When observational studies assess risk of fracture in patients with TZDs, the severity of T2DM should be taken into account.
| Item Type: | Article |
|---|---|
| ISSNs: | 1053-8569 (print) 1099-1557 (electronic) |
| Keywords: | thiazolidinediones, type 2 diabetes mellitus, fracture risk, osteoporosis, adverse events |
| Subjects: | R Medicine > RB Pathology R Medicine > RS Pharmacy and materia medica |
| Divisions: | Faculty of Health Sciences |
| Item ID: | 340341 |
| Date Deposited: | 19 Jun 2012 15:24 |
| Last Modified: | 29 May 2013 01:09 |
| Contributors: | Bazelier, Marloes T. (Author) Gallagher, Arlene M. (Author) van Staa, Tjeerd-Pieter (Author) Cooper, Cyrus (Author) Leufkens, Hubert G. M. (Author) Vestergaard, Peter (Author) de Vries, Frank (Author) |
| Date: | May 2012 |
| Status: | Published |
| URI: | http://eprints.soton.ac.uk/id/eprint/340341 |
Actions (login required)
 |
View Item |
